NASDAQ:ALNY Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis → Nvidia’s Quiet $1 Trillion Pivot (From Weiss Ratings) (Ad) Free ALNY Stock Alerts $152.78 +3.48 (+2.33%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$147.25▼$152.9550-Day Range$143.31▼$156.0452-Week Range$141.98▼$218.88Volume862,730 shsAverage Volume573,842 shsMarket Capitalization$19.33 billionP/E RatioN/ADividend YieldN/APrice Target$216.19 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Alnylam Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.59 Rating ScoreUpside/Downside41.5% Upside$216.19 Price TargetShort InterestHealthy2.01% of Shares Sold ShortDividend StrengthN/ASustainability-1.52Upright™ Environmental ScoreNews Sentiment1.47Based on 9 Articles This WeekInsider TradingSelling Shares$3.22 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.77) to ($2.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.76 out of 5 starsMedical Sector56th out of 904 stocksPharmaceutical Preparations Industry17th out of 429 stocks 4.3 Analyst's Opinion Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.59, and is based on 10 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alnylam Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.01% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently decreased by 3.42%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlnylam Pharmaceuticals has received a 63.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Gene therapy medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alnylam Pharmaceuticals is -1.52. Previous Next 4.1 News and Social Media Coverage News SentimentAlnylam Pharmaceuticals has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Alnylam Pharmaceuticals this week, compared to 8 articles on an average week.Search Interest7 people have searched for ALNY on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows6 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,224,620.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alnylam Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($3.77) to ($2.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is -57.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is -57.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Alnylam Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanySecret energy grid to power millions of homesThis high-security, secret U.S. facility has 2,100 engineers, machinists, and technicians building a new type of energy system the world has never seen before.Click here to get all the details. About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Read More ALNY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALNY Stock News HeadlinesJune 1, 2024 | insidertrades.comAmy W. Schulman Sells 21,700 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) StockJune 5 at 6:14 AM | investorplace.comJune's Biotech Boom: 3 Stocks to Buy for a Summertime SurgeJune 3, 2024 | seekingalpha.comUpcoming Pivotal HELIOS-B Data Looms Large For Alnylam's ValuationJune 3, 2024 | americanbankingnews.comInsider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Sells 21,700 Shares of StockMay 29, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) & Vaccinex (NASDAQ:VCNX) Head to Head AnalysisMay 16, 2024 | benzinga.comMarket Whales and Their Recent Bets on ALNY OptionsMay 15, 2024 | finance.yahoo.comThe Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) First-Quarter Results Are Out And Analysts Have Published New ForecastsMay 15, 2024 | finance.yahoo.comAlnylam Issues 2023 Corporate Responsibility ReportMay 10, 2024 | fool.comAlnylam Pharmaceuticals Outperformed in Q1May 9, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Viridian Therapeutics (VRDN)May 9, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Cytokinetics (CYTK)May 7, 2024 | finance.yahoo.comPureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive AppointmentsMay 3, 2024 | finance.yahoo.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call TranscriptMay 3, 2024 | markets.businessinsider.comStrong Financial Growth and Promising Clinical Trials Bolster Buy Rating for Alnylam PharmaceuticalsMay 3, 2024 | finance.yahoo.comAlnylam Pharmaceuticals First Quarter 2024 Earnings: Beats ExpectationsMay 3, 2024 | finance.yahoo.comAlnylam Pharmaceuticals Inc (ALNY) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...May 2, 2024 | sfgate.comAlnylam: Q1 Earnings SnapshotMay 2, 2024 | investorplace.comALNY Stock Earnings: Alnylam Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | seekingalpha.comAlnylam Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 2, 2024 | msn.comAlnylam Pharmaceuticals Non-GAAP EPS of -$0.16 beats by $0.32, revenue of $494.3M beats by $67.44MMay 2, 2024 | businesswire.comAlnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period ActivityMay 1, 2024 | markets.businessinsider.comHere's what Wall Street expects from Alnylam Pharmaceuticals's earningsApril 30, 2024 | markets.businessinsider.comAlnylam, Medison Expand Partnership To Market RNAi Therapeutics In Addnl. LATAM And APAC MarketsApril 30, 2024 | prnewswire.comMedison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including AustraliaApril 29, 2024 | insidermonkey.com5 Most Promising Stocks to Buy Before They Take OffSee More Headlines Company Calendar Last Earnings5/02/2024Today6/08/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALNY CUSIP02043Q10 CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$216.19 High Stock Price Target$400.00 Low Stock Price Target$161.00 Potential Upside/Downside+41.5%Consensus RatingModerate Buy Rating Score (0-4)2.59 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-440,240,000.00 Net Margins-16.58% Pretax Margin-16.21% Return on EquityN/A Return on Assets-8.92% Debt Debt-to-Equity RatioN/A Current Ratio3.17 Quick Ratio3.07 Sales & Book Value Annual Sales$1.83 billion Price / Sales10.57 Cash FlowN/A Price / Cash FlowN/A Book Value($1.76) per share Price / Book-86.81Miscellaneous Outstanding Shares126,490,000Free Float124,595,000Market Cap$19.33 billion OptionableOptionable Beta0.30 Social Links Key ExecutivesDr. Yvonne L. Greenstreet M.B.A. (Age 61)MBChB, CEO & Director Comp: $2.15MMr. Jeffrey V. Poulton M.B.A. (Age 56)CFO & Executive VP Comp: $1.05MDr. Akshay K. Vaishnaw M.D. (Age 61)Ph.D., Chief Innovation Officer & Member of the Scientific Advisory Board Comp: $1.12MDr. Pushkal P. Garg M.D. (Age 56)Chief Medical Officer and Executive VP of Development & Medical Affairs Comp: $1.06MMr. Tolga Tanguler M.B.A. (Age 51)Executive VP & Chief Commercial Officer Comp: $971.3kMr. Timothy J. MainesChief Technical Operations & Quality OfficerDr. Kevin Joseph Fitzgerald Ph.D. (Age 55)Senior VP, Head of Research & Chief Scientific Officer Ms. Christine Regan Lindenboom (Age 43)Senior VP of Investor Relations & Corporate Communications Mr. Piyush Sharma J.D.Chief Ethics & Compliance OfficerMr. Evan Lippman M.B.A.Chief Corporate Development & Strategy OfficerMore ExecutivesKey CompetitorsRoyalty PharmaNASDAQ:RPRXBeiGeneNASDAQ:BGNEMyoKardiaNASDAQ:MYOKSarepta TherapeuticsNASDAQ:SRPTHorizon Therapeutics PublicNASDAQ:HZNPView All CompetitorsInsiders & InstitutionsDekaBank Deutsche GirozentraleSold 24,843 shares on 6/4/2024Ownership: 0.089%Amy W SchulmanSold 21,700 sharesTotal: $3.22 M ($148.60/share)Teachers Retirement System of The State of KentuckyBought 2,500 shares on 5/28/2024Ownership: 0.026%Cetera Advisors LLCBought 1,593 shares on 5/24/2024Ownership: 0.001%Burney Co.Bought 21,325 shares on 5/22/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.: Alnylam Pharmaceuticals has a diverse portfolio of marketed products, including ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO, targeting various rare diseases, providing a stable revenue stream. The company has received positive ratings from analysts, with a consensus rating of "Moderate Buy" and an average target price of $216.19, indicating growth potential. Institutional investors have been increasing their holdings in Alnylam Pharmaceuticals, signaling confidence in the company's future prospects. Recent developments show that Alnylam Pharmaceuticals stock has a 52-week low of $141.98, potentially presenting a buying opportunity for investors seeking value. Alnylam Pharmaceuticals focuses on innovative therapeutics based on ribonucleic acid interference, positioning itself at the forefront of biopharmaceutical advancements. Cons Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons: Alnylam Pharmaceuticals stock has experienced fluctuations, with a 52-week high of $218.88, indicating potential volatility in the market. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, June 2, 2024. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com. ALNY Stock Analysis - Frequently Asked Questions Should I buy or sell Alnylam Pharmaceuticals stock right now? 17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 7 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALNY shares. View ALNY analyst ratings or view top-rated stocks. What is Alnylam Pharmaceuticals' stock price target for 2024? 17 equities research analysts have issued 12-month price targets for Alnylam Pharmaceuticals' stock. Their ALNY share price targets range from $161.00 to $400.00. On average, they expect the company's share price to reach $216.19 in the next year. This suggests a possible upside of 41.5% from the stock's current price. View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts. How have ALNY shares performed in 2024? Alnylam Pharmaceuticals' stock was trading at $191.41 at the start of the year. Since then, ALNY shares have decreased by 20.2% and is now trading at $152.78. View the best growth stocks for 2024 here. When is Alnylam Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our ALNY earnings forecast. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its quarterly earnings data on Thursday, May, 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.23. The biopharmaceutical company had revenue of $494.33 million for the quarter, compared to the consensus estimate of $428.01 million. The business's revenue was up 54.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.40) EPS. What ETFs hold Alnylam Pharmaceuticals' stock? ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Morningstar US Small Growth (MSGR), Amplify Treatments, Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Fidelity Disruptive Medicine ETF (FMED), Principal Healthcare Innovators ETF (BTEC), Tema Cardiovascular and Metabolics ETF (HRTS) and Horizon Kinetics Medical ETF (MEDX). What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings? Alnylam Pharmaceuticals updated its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.7 billion-$1.9 billion, compared to the consensus revenue estimate of $1.9 billion. What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO? 65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD). Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Capital World Investors (10.11%), Vanguard Group Inc. (9.48%), Baillie Gifford & Co. (5.26%), Price T Rowe Associates Inc. MD (2.91%), Capital International Investors (2.89%) and Capital Research Global Investors (2.49%). Insiders that own company stock include Akshay Vaishnaw, Amy W Schulman, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Michael W Bonney, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALNY) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredWarren Buffett & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Alnylam Pharmaceuticals, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.